Johnson County Healthcare Center

*DO NOT USE013020

29125 APPLICATION OF SHORT ARM SPLINT (FOREARM TO HAND); STA

29130 ed proc application of finger splint static

37799 ed proc vascular surgery unlisted proc

3D RENDERING WITH INTERPRETATION AND REPORTING OF COMPUTED TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, ULTRASOUND, OR OTHER TOMOGRAPHIC MODALITY WITH IMAGE POSTPROCESSING UNDER CONCURRENT SUPERVISION; NOT REQUIRING IMAGE POSTPROCESSING ON AN INDEPENDENT WORKSTATION

58160-0890-52 - influenza virus vaccine, inactivated preservative-free quadrivalent Sus [MEMO]

ABDOMINAL PARACENTESIS (DIAGNOSTIC OR THERAPEUTIC); WITH IMAGING GUIDANCE

ABL1 (ABL PROTO-ONCOGENE 1, NON-RECEPTOR TYROSINE KINASE) (EG, ACQUIRED IMATINIB TYROSINE KINASE INHIBITOR RESISTANCE), GENE ANALYSIS, VARIANTS IN THE KINASE DOMAIN

ACETAZOLAMIDE LESS THAN500MG 500MG 5MLSNIJ

ACETYLCYSTEINE 200 MG/ML (20 %) INTRAVENOUS SOLUTION [35100]

ACETYLCYSTEINE, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE FORM, PER GRAM

ACNE SURGERY (EG, MARSUPIALIZATION, OPENING OR REMOVAL OF MULTIPLE MILIA, COMEDONES, CYSTS, PUSTULES)

ACTIN (SMOOTH MUSCLE) ANTIBODY (ASMA), EACH

ACUTE HEPATITIS PANEL THIS PANEL MUST INCLUDE THE FOLLOWING: HEPATITIS A ANTIBODY (HAAB), IGM ANTIBODY (86709) HEPATITIS B CORE ANTIBODY (HBCAB), IGM ANTIBODY (86705) HEPATITIS B SURFACE ANTIGEN (HBSAG) (87340) HEPATITIS C ANTIBODY (86803)

ACYCLOVIR SODIUM 50 MG/ML INTRAVENOUS SOLUTION [4235]

ADALIMUMAB CONC & ABS (LCP 503890)

ADMINISTRATION OF HEPATITIS B VACCINE

ADMINISTRATION OF INFLUENZA VIRUS VACCINE

ADMINISTRATION OF PNEUMOCOCCAL VACCINE

ADRENOCORTICOTROPIC HORMONE (ACTH) LEVEL

ADVANCE CARE PLANNING INCLUDING THE EXPLANATION AND DISCUSSION OF ADVANCE DIRECTIVES SUCH AS STANDARD FORMS (WITH COMPLETION OF SUCH FORMS, WHEN PERFORMED), BY THE PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL; EACH ADDITIONAL 30 MINUTES (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

ADVANCE CARE PLANNING INCLUDING THE EXPLANATION AND DISCUSSION OF ADVANCE DIRECTIVES SUCH AS STANDARD FORMS (WITH COMPLETION OF SUCH FORMS, WHEN PERFORMED), BY THE PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL; FIRST 30 MINUTES, FACE-TO-FACE WITH THE PATIENT, FAMILY MEMBER(S), AND/OR SURROGATE

AFP TETRA (LCP 017319)(ESTRIOL)

AFP TETRA (LCP 017319)(INHIBIN A)

AGALSIDASE BETA 1MG 35MG 7ML PWIJ

ALBUMIN; URINE (EG, MICROALBUMIN), SEMIQUANTITATIVE (EG, REAGENT STRIP ASSAY)

ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME, UNIT DOSE, 1 MG

ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG, FDA-APPROVED FINAL PRODUCT, NON-COMPOUNDED, ADMINISTERED THROUGH DME

ALCOHOL (ETHANOL); ANY SPECIMEN EXCEPT URINE AND BREATH, IMMUNOASSAY (EG, IA, EIA, ELISA, RIA, EMIT, FPIA) AND ENZYMATIC METHODS (EG, ALCOHOL DEHYDROGENASE)

ALLERGEN SPECIFIC IGE; QUALITATIVE, MULTIALLERGEN SCREEN (EG, DISK, SPONGE, CARD)

ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, CRUDE ALLERGEN EXTRACT, EACH

ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, RECOMBINANT OR PURIFIED COMPONENT, EACH

ALPHA-1-ANTITRYPSIN (PROTEIN) BLOOD TEST, PHENOTYPE

ALT- BC

ALTEPLASE 2 MG INTRA-CATHETER SOLUTION [19101]

AMB SILVER SULFADIAZINE TOPICAL 1% 50GM CREAM

AMBULATORY BLOOD PRESSURE MONITORING, UTILIZING REPORT-GENERATING SOFTWARE, AUTOMATED, WORN CONTINUOUSLY FOR 24 HOURS OR LONGER; REVIEW WITH INTERPRETATION AND REPORT

AMBULATORY CONTINUOUS GLUCOSE MONITORING OF INTERSTITIAL TISSUE FLUID VIA A SUBCUTANEOUS SENSOR FOR A MINIMUM OF 72 HOURS; ANALYSIS, INTERPRETATION AND REPORT

AMBULATORY CONTINUOUS GLUCOSE MONITORING OF INTERSTITIAL TISSUE FLUID VIA A SUBCUTANEOUS SENSOR FOR A MINIMUM OF 72 HOURS; PHYSICIAN OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL (OFFICE) PROVIDED EQUIPMENT, SENSOR PLACEMENT, HOOK-UP, CALIBRATION OF MONITOR, PATIENT TRAINING, REMOVAL OF SENSOR, AND PRINTOUT OF RECORDING

AMINO ACIDS, 6 OR MORE AMINO ACIDS, QUANTITATIVE, EACH SPECIMEN

AMPICILLIN 500 MG SOLUTION FOR INJECTION [13513]

AMPICILLIN-SULBACTAM 1.5 GRAM SOLUTION FOR INJECTION [14372]

AMPUTATION OF TOE AT JOINT BETWEEN FOREFOOT AND TOES

ANALYSIS FOR ANTIBODY (IGM) TO CYTOMEGALOVIRUS (CMV)

ANALYSIS FOR ANTIBODY BORRELIA BURGDORFERI (LYME DISEASE BACTERIA)

ANALYSIS FOR ANTIBODY TO CYTOMEGALOVIRUS (CMV)

ANALYSIS FOR ANTIBODY TO EHRLICHIA (BACTERIA TRANSMITTED BY TICKS)

ANALYSIS FOR ANTIBODY TO EPSTEIN-BARR VIRUS (MONONUCLEOSIS VIRUS), NUCLEAR ANTIGEN

ANALYSIS FOR ANTIBODY TO EPSTEIN-BARR VIRUS (MONONUCLEOSIS VIRUS), VIRAL CAPSID

ANALYSIS FOR ANTIBODY TO HERPES SIMPLEX VIRUS, TYPE 1